Mariano Rincon

Dr. Mariano Rincon

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in Artificial Intelligence in Medicine
Verified
Journal Article
Closed access
Enrique J. CarmonaEnrique J. Carmona
Enrique J. Carmona
MRMariano Rincon
Mariano Rincon
JGJulián García-Feijóo
Julián García-Feijóo
Jose M Martinez de la CasaJose M Martinez de la Casa
Jose M Martinez de la Casa

3 June 2015 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
PSPer Selnes
Per Selnes
RGRamune Grambaite
Ramune Grambaite
MRMariano Rincon
Mariano Rincon
ABAtle Bjørnerud
Atle Bjørnerud
LGLeif Gjerstad
Leif Gjerstad
TFTormod Fladby
Tormod Fladby
To investigate putative interacting or distinct pathways for hippocampal complex substructure (HCS) atrophy and cognitive affection in early-stage Alzheimer's disease (AD) and cerebrovascular disease (CVD), we recruited healthy controls, patients with mild cognitive impairment (MCI) and poststroke patients. HCSs were segmented, and quantitative white-matter hyperintensity (WMH) load and cerebrospinal fluid (CSF) amyloid-β concentrations were determined. The WMH load was higher poststroke. All examined HCSs were smaller in amyloid-positive MCI than in controls, and the subicular regions were smaller poststroke. Memory was reduced in amyloid-positive MCI, and psychomotor speed and executive function were reduced in poststroke and amyloid-positive MCI. Size of several HCS correlated with WMH load poststroke and with CSF amyloid-β concentrations in MCI. In poststroke and amyloid-positive MCI, neuropsychological function correlated with WMH load and hippocampal volume. There are similar patterns of HCS atrophy in CVD and early-stage AD, but different HCS associations with WMH and CSF biomarkers. WMHs add to hippocampal atrophy and the archetypal AD deficit delayed recall. In line with mounting evidence of a mechanistic link between primary AD pathology and CVD, these additive effects suggest interacting pathologic processes.

13 November 2007 in Pattern Recognition Letters
Verified
Journal Article
Closed access
RMR. Martínez-Tomás
R. Martínez-Tomás
MRMariano Rincon
Mariano Rincon
MBM. Bachiller
M. Bachiller
JMJ. Mira
J. Mira

1 January 2016 in Methods of Information in Medicine
Verified
Journal Article
Closed access
PDF file
JGJ. M. Guerrero
J. M. Guerrero
MRMariano Rincon
Mariano Rincon
HPH. Peraita
H. Peraita
RMR. Martínez-Tomás
R. Martínez-Tomás
Summary: Background: Early detection of Alzheimer’s disease (AD) has become one of the principal focuses of research in medicine, particularly when the disease is incipient or even prodromic, because treatments are more effective in these stages. Lexical-semantic- conceptual deficit (LSCD) in the oral definitions of semantic categories for basic objects is an important early indicator in the evaluation of the cognitive state of patients. Objectives: The objective of this research is to define an economic procedure for cognitive impairment (CI) diagnosis, which may be associated with early stages of AD, by analysing cognitive alterations affecting declarative semantic memory. Because of its low cost, it could be used for routine clinical evaluations or screenings, leading to more expensive and selective tests that confirm or rule out the disease accurately. It should necessarily be an explanatory procedure, which would allow us to study the evolution of the disease in relation to CI, the irregularities in different semantic categories, and other neurodegenerative diseases. On the basis of these requirements, we hypothesise that Bayesian networks (BNs) are the most appropriate tool for this purpose. Methods: We have developed a BN for CI diagnosis in mild and moderate AD patients by analysing the oral production of semantic features. The BN causal model represents LSCD in certain semantic categories, both of living things (dog, pine, and apple) and non-living things (chair, car, and trousers), as symptoms of CI. The model structure, the qualitative part of the model, uses domain knowledge obtained from psychology experts and epidemiological studies. Further, the model parameters, the quantitative part of the model, are learnt automatically from epidemiological studies and Peraita and Grasso’s linguistic corpus of oral definitions. This corpus was prepared with an incidental sampling and included the analysis of the oral linguistic production of 81 participants (42 cognitively healthy elderly people and 39 mild and moderate AD patients) from Madrid region’s hospitals. Experienced neurologists diagnosed these cases following the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDSADRDA)’s Alzheimer’s criteria, performing, among other explorations and tests, a minimum neuropsychological exploration that included the Mini-Mental State Examination test. Results: BN’s classification performance is remarkable compared with other machine learning methods, achieving 91% accuracy and 94% precision in mild and moderate AD patients. Apart from this, the BN model facilitates the explanation of the reasoning process and the validation of the conclusions and allows the study of uncommon declarative semantic memory impairments. Conclusions: Our method is able to analyse LSCD in a wide set of semantic categories throughout the progression of CI, being a valuable first screening method in AD diagnosis in its early stages. Because of its low cost, it can be used for routine clinical evaluations or screenings to detect AD in its early stages. Besides, due to its knowledge-based structure, it can be easily extended to provide an explanation of the diagnosis and to the study of other neurodegenerative diseases. Further, this is a key advantage of BNs over other machine learning methods with similar performance: it is a recognisable and explanatory model that allows one to study irregularities in different semantic categories.

28 January 2025 in JMIR Medical Informatics
Verified
Journal Article
Open access
MPMaría de la Paz Scribano Parada
María de la Paz Scribano Parada
FPFátima González Palau
Fátima González Palau
VSValladares-Rodriguez Sonia
Valladares-Rodriguez Sonia
MRMariano Rincon
Mariano Rincon
MBMaria José Rico Barroeta
Maria José Rico Barroeta
RDRaquel Losada Durán
Raquel Losada Durán
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: In today's context, widespread healthcare access and changing living conditions contribute to an aging population, escalating the prevalence of Neurocognitive Disorders (NCD). This shift poses societal challenges and strains healthcare systems, emphasizing the urgent need for pharmacological interventions to address Alzheimer's Disease (AD) progression. Despite efforts, a universally effective pharmacological solution remains elusive. Simultaneously, studies highlight that factors like education, healthy lifestyles, and social engagement can delay AD onset. Identifying early markers, particularly in the preclinical stage, becomes crucial. The preclinical stage, characterized by evidence of AD pathology without cognitive or behavioral impairment, prompts the quest for early biomarkers. Current biomarkers, while valuable, face challenges of cost, limited availability, and inconclusive correlation with clinical manifestations. This underscores the necessity for alternative cognitive-behavioral markers, with recent studies exploring domains beyond episodic memory. Moreover, advancements incorporating Artificial Intelligence (AI) and Machine Learning (ML) aim to integrate neuroimaging, neuropsychological variables, and biomarkers for early AD diagnosis. Additionally, the exploration of Virtual Reality (VR) environments presents a novel avenue for diagnostics Objective: This project systematically reviews neurocognitive markers in preclinical AD diagnosis, emphasizing recent studies involving VR. A secondary objective is to discern tests with the highest evidentiary support for each proposed domain. Methods: Methods: The article selection process involved an initial search using specific keywords, such as "memory AND longitudinal AND Alzheimer's disease," "mild cognitive impairment AND (Alzheimer's disease OR dementia) AND neuropsychology AND (prediction OR longitudinal)," and "Alzheimer's disease AND conversion AND neuropsychology." However, this initial search did not yield any papers discussing virtual reality tools for diagnosis. To address this, additional terms, including "virtual reality," were incorporated into the search strategy. This adjustment resulted in the identification of 13 new papers, with 11 fully integrated into the study. Notably, two review papers from this subset are discussed in the later sections. Two papers were excluded due to their focus on rehabilitation rather than the intended diagnostic scope Results: Results: Selected articles highlight verbal episodic memory, measured by various tests, as the earliest, most sensitive marker for preclinical Alzheimer's Disease (AD). Neuroimaging, genetic profiling (APOE), and CSF markers (A$beta$, tau, p-tau) complement this assessment. Notable studies detail the sequence of cognitive decline, with executive functions preceding memory failure. Speed of processing emerges as a significant correlate, surpassing MRI patterns for functional outcomes. Limited literature explores virtual reality's potential for early diagnosis, with some studies demonstrating its efficacy in assessing visuospatial and memory functions. Promisingly, AI algorithms, coupled with advanced diagnostic tools, offer a multidimensional approach for accurate early diagnosis of neurocognitive disorders. Conclusions: The preclinical diagnosis of neurocognitive disorders is challenging, with emerging tools like VR and AI offering potential but also posing obstacles such as cost, rigorous validation, and the need for expert interpretation. Ethical concerns regarding patient data in virtual environments require attention. Despite challenges, the evolving role of VR in Alzheimer's diagnosis signifies a promising advancement in healthcare. Continued technological refinement is expected to enhance early identification and management, demanding thorough validation and regulation for clinical efficacy and safety.

22 June 2007
Verified
Book Chapter
Closed access
PDF file
EFE. Folgado
E. Folgado
MRMariano Rincon
Mariano Rincon
JÁJ. R. Álvarez
J. R. Álvarez
JMJ. Mira
J. Mira